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In Hospitals
William Jarvis, Centers for Disease Control
and Prevention (CDC), discussed antimicrobial
resistance related to hospitalization. Two major
factors contribute to the emergence and spread of
antimicrobial resistance in hospitals: a high rate
of antimicrobial drug use and inadequate
infection control practices. Much antimicrobial
drug use in hospitals is inappropriate (e.g., the
use of vancomycin to treat a staphylococcal
infection susceptible to methicillin, or the
continuation of perioperative prophylaxis beyond
24 to 48 hours). Educational efforts on
antimicrobial drug use in hospitals have had
mixed success. More aggressive and controver-
sial approaches to improve the use of these drugs
have been proposed; for example, excluding
certain drugs (such as vancomycin) from the
routine reporting of susceptibility results;
monitoring antimicrobial use with feedback to
physicians concerning inappropriate use; anti-
biotic-use audits targeting problem areas (e.g., no
diagnostic test done, more than four drugs used
during one hospitalization, use for more than 3
weeks continuously); regulating drug promotion;
requiring justifications for use; using computer-
generated stop orders; and developing formular-
ies, restrictions, and protocols by a
multidisciplinary team.
In Communities
Keith Klugman, South African Institute of
Medical Research, spoke on community-acquired
infections, focusing on respiratory pathogens.
One controversial area concerns the extent to
which drug resistance identified in the microbiol-
ogy laboratory correlates with clinical failure.
Since clinical trial data are frequently unavail-
able, assessment of drug efficacy is often based on
pharmacodynamics; i.e., a drug is believed
efficacious if its concentration at the site of
infection exceeds the organism’s MIC. Otitis
media and meningitis studies support this
approach. In Pakistan, laboratory data indicate
that 78% of pneumococci are resistant to co-
trimoxazole, yet the clinical treatment failure
rate is only 15%. The reasons for this discrepancy
are unknown, but the issue is important because
alternative drugs are more expensive. Standard-
ization of laboratory methods and appropriate
surveillance methods are essential.
Another controversial area involves anti-
biotic use and how to improve it. For many
infections, the optimal dose and duration of
therapy are unknown. Antibiotics are often
prescribed inappropriately because physicians
are uncertain when antibiotics are indicated and
patients demand them; educating both of these
groups is a challenge. Better diagnostics to
reduce empiric therapy would be helpful. Other
areas of uncertainty include the use of vaccines to
decrease colonization and infection with resis-
tant organisms and the extent to which
antibiotics given for a specific indication might
lead to resistance in different organisms.
In Veterinary Medicine
Klaus Stoehr, World Health Organization
(WHO), addressed controversies related to use of
antibiotics (preventive, therapeutic, growth-
promoting) in food animals. Some antibiotic use
contributes to the pool of resistant human
pathogens. Both medical and nonmedical uses of
antibiotics should be reduced. More scientific
data are needed to address issues related to
antibiotic use in food animals, including
elucidating the human health impact, e.g., the
percentage of resistance genes or resistant
organisms originating in animals and the extent
to which therapy of zoonotic bacterial infections
in humans has been compromised because of
resistance. The economic benefits of
subtherapeutic antimicrobial use for growth
promotion are also controversial; one study
estimates that production costs without such use
would increase by up to 8%, but recent experience
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in Sweden indicates that meat produced without
growth promotants can be priced competitively.
A WHO meeting in 1997 on the medical impact of
antibiotic use in livestock production recom-
mended antimicrobial resistance monitoring and
prudent use of antibiotics in food animals.
In Developing Countries
Antonio C. Pignatari, Escola Paulista da
Medicina, São Paulo, Brazil, discussed antibiotic
resistance issues in developing countries. More
than two thirds of the world’s population lives in
developing countries, where the contrast be-
tween wealth and poverty is extreme. Infectious
diseases represent the main public health
problem. Because of inadequate resources for
surveillance, control, and treatment, antimicro-
bial-resistant infections have become a major
problem with serious implications for the health
system and the economy. The main problems
with drug resistance are seen in the treatment of
diarrheal diseases, sexually transmitted dis-
eases, pneumococcal infections, tuberculosis,
nosocomial infections, and malaria. Restrictive
antimicrobial use policies (which are controver-
sial) can be effective in the hospital but are
difficult to implement in the community. In many
areas, the availability of medical care is limited;
thus, laws requiring a physician’s prescription for
antibiotics are difficult to enforce. Pharmacies
provide an important service in dispensing
medications, yet most developing country
pharmacists have limited training. The use of
antimicrobial drugs in food animals is also a
problem in developing countries, and no controls
are in place to address it. Control of antimicrobial
resistance and emerging infections in developing
countries cannot be achieved without addressing
closely related social and economic issues.
In Clinical Laboratories
Fred Tenover, CDC, addressed antibiotic
resistance issues in the microbiology laboratory.
Laboratorians must move from susceptibility
testing to finding resistance. A common
misconception is that new resistance mecha-
nisms are easily identified because they result in
high MICs and low zone sizes. However, many
new resistance mechanisms lead to MICs close to
the breakpoint for resistance. More sensitive
screening tests are being introduced to detect
resistance, but they cannot replace MICs;
therefore, laboratory workload is increasing in an
era of downsizing.
Several “drug-bug” combinations are prob-
lematic and require new approaches. For
detecting nonsusceptibility (intermediate or full
resistance) of staphylococci to vancomycin, the
traditional method of disk diffusion testing is not
reliable. Acceptable methods include the Brain
Heart Infusion vancomycin agar screening test
developed for enterococci or broth microdilution
tests held 24 hours. For pneumococci, testing for
susceptibility to both penicillin and extended
spectrum cephalosporins is important because
resistance to these drugs is becoming more
common. For invasive isolates where the need to
detect resistance is urgent, the oxacillin
screening test should not be used; MIC methods
should be used directly. For gram-negative
bacilli, traditional methods to detect resistance to
extended spectrum beta-lactam drugs are
inadequate, although the latest National Com-
mittee for Clinical Laboratory Standards guide-
lines present effective screening tests. Finally,
sensitivity must be determined for clinically
important isolates treated with fluoroquinolones,
since selective pressure for resistance is
increasing as a result of widespread use.